Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% to $600 million and ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by ...
NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback